Haldol

Pediatric Use Controlled trials to establish the safety and effectiveness of intramuscular administration in children have not been conducted. Adverse Reactions: Adverse reactions following the administration of HALDOL haloperidol ; Decanoate are those of HALDOL. Since vast experience has accumulated with HALDOL, the adverse reactions are reported for that compound as well as for HALDOL Decanoate. As with all injectable medications, local tissue reactions have been reported with HALDOL Decanoate. cws Effects: Extrapyramidal Reactions-Neuromuscular extrapyramidal ; reacboos have been reported frequently often during the first few days of treatment. Generally they involved Parkinson-like symptoms which when first observed were usually mild to moderately severe and usually reversible. Other types of neuromuscular reactions motor restlessness, dystonia and tardive dystonia, akathisia, hyperreflexia, opisthotonos, oculogyric crises ; have been reported far less frequently, but were often more severe. Severe extrapyramidal reactions have been reported at relatively low doses. Generally, extrapyramidal symptoms are dose-related since they occur at relatively high doses and disappear or become less severe when the dose is reduced. Antiparkinson drugs may be required. Persistent extrapyramidal reactions have been reported and the drug may have to be discontinued in such cases. Withdrawal Emergent Neurological Signs-Abrupt discontinuation of short-term antipsychotic therapy is generally uneventful. However, some patients on maintenance treatment experience transient dyskinetic signs after abrupt withdrawal. In certain cases these are indistinguishable from Tardive Dyskinesia except for duration. It is unknown whether 9radual withdrawal will reduce the occurrence of these signs. but until further evidence is available HALDOL should be gradually withdrawn. Tardive Dyskinesia-As with alt antipsychotic agents HALDOL has been associated with persistent dyskinesias. Tardive dyskinesia, a syndrome consisting ofpotentially irreversible, involuntary. dyskinetic movements, may appear in some patients on long-term therapy or may occur after drug therapy has been discontinued. The risk appears to be greater in elderly patients on high-dose therapy, especially females. The symptoms are persistent and in some patients appear irreversible. The syndrome is charactetized by rhythmical involuntary movements of tongue, face, mouthorjaw e.g., protrusion of tongue. puffing of cheeks puckering of mouth, chewing movements ; . Sometimes these may be accompanied by involuntary movementsof extremities and the trunk. There is no known effective treatment fortardive dyskinesia; antiparkinson agents usually do not alleviate the symptoms of this syndrome. It is suggested that alt antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage ofthe agent. or switch to a different antipsychotic agent, this syndrome may be masked. ft has been reported that fine vermicular movement of the tongue may be an early sign of tardive dyskinesia and if the medication is stopped at that time the full syndrome may not develop. Other C1'IS Effects Insomnia, restlessness, anxiety, euphoria, agitation, drowsiness, depression, lethargy. headache, confusion, vertig grand mal seizures, and exacerbation of psychotic symptoms including hallucinations, and catatonic-like behavioralstates which may be responsivetodrug withdrawal and or treatmentwith antichoilnergic drugs. Body as a Whole Neuroleptic Malignant Syndrome' As with other antipsychotic drugs, a symptom complex sometimes referred to as neuroleptic malignant syndrome NMS ; has been reported. Cardinal features of NMS are hyperpyrexia, muscle rigidity, altered mental status including catatonic signs and evidence of autonomic instabllity irregular pulse or blood pressure ; . Additional signs may include elevated creatinine phosphokinase, myogloblnuna rhabdomyolysis ; , and acute renal failure. NMS is potentially fatal, requires intensive symptomatic treatment and Immediate discontinuation of antipsychotic treatment. Hyperpyrexia and heat stroke, not associated with the above symptom complex, have also been reported. Cardlovascu!arEffects: Tachycardia, hypotension, hypertension and ECG changes. Hematologic Effecfs Reports of mild, usually transient leukopenia and leukocytosis, minimal decreases in red blood cell counts, anemia, or a tendency toward lymphomonocytosls; agranulocytosis rarely reported and only in association with other medication. Liver Effects: Impaired liver function and or jaundice. Dermatoloq!c Reactions: Maculopapular and acneiform reactions, isolated cases of photosensitivity, loss of hair. Endocrine Disorders: Lactation, breast engorgement, rnastalgia, menstrual irregularities, gynecornastia, impotence, increased libidQ hyperglycemia, hypoglycemia and hyponatremia. Gastrointestinal Effectr Anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea and vomiting. Autorsomic Reactions: Dry mouth, blurred vision, urlnary retention, diaphoresis, and priapism. Respiratory Effects: L.aryngospasm, bronchospasm and increased depth of respiration. Special Senses: Cataracts, retinopathy and visual disturbances. Other: Cases of sudden and unexpected death have been reported in association with the administration of HALDOL. The nature of the evidence makes it impossible to determine definitively what role, if any. HALDOL played in the outcome of the reported cases. The possibility that HALDOL caused death cannot, of course, be excluded, but it Is to kept In mind that sudden and unexpected death may occur in psychotic patients when they go untreated or when they are treated with other antipsychotic drugs. IMPORTANT: Full directions for use should be read before HALDOL or HALDOL Decanoatels administered or prescribed. Forinformatlon on symptoms and treatment of overdosage, see full prescribIng Information. The short-acting HALDOL injectable form is intended only for acutely agitated psychotic patients with moderately severeto very severe symptoms.

Stated he had not been scheduled for follow-up and there was no evidence in the record of monitoring. The most troublesome report was from an inmate 154941 ; who stated he had been prescribed Haldlo while at Taylor Hardin but he had not received the medication for the three weeks he had been at Kilby. It is disturbing that four of fifteen of the inmates receiving psychotropic medication in general population credibly reported problems with mental health services. If we had been permitted access during the visit to speak with mental health staff, it is possible that these reported problems would have been explained by staff. Two of the fifteen general population inmates interviewed also reported there were inmates in their dormitories who appeared to have serious mental illness. The inmates described the inmate bed locations but were unable to provide the inmate names. Thus, we were unable to interview these inmates. INFIRMARY MENTAL HEALTH CELLS Kilby has twelve single cell infirmary cells located in the South, East and West Ward Isolation areas. These cells are not dedicated for mental health treatment and plainly should not be part of any count of mental health beds. While there are also forty-one infirmary dormitory beds, dormitory beds are inappropriate for the treatment of inmates requiring mental health crisis stabilization. ST. CLAIR CORRECTIONAL FACILITY Our site visit of St. Clair Correctional Facility was conducted on Tuesday, March 14, 2000. St. Clair is a male, maximum-security institution with an inmate census of approximately 1330. General population inmates are housed in dormitories. There are 216 segregation cells used interchangeably for administrative and disciplinary placements. There are three cells in the infirmary designated for mental health crises. One additional single cell and a sixteen-bed dormitory are reportedly available for some mental health care as well as medical treatment.
ANTUNES-RODRIGUES ET AL. trol of fluid homeostasis and arterial pressure. Clin Exp Pharmacol Physiol 27: 443 449, Ota M, Crofton JT, and Festavan GT. Share evidence that nitric oxide can act centrally to stimulate vasopressin release. Neuroendocrinology 57: 955959, 1993. Otake K, Kondo K, and Oiso Y. Possible involvement of endogenous opioid peptides in the inhibition of arginine vasopressin release by gamma-aminobutyric acid in conscious rats. Neuroendocrinology 54: 170 174, Ouan A and Baum M. The renal nerve is required for regulation of proximal tubule transport by intraluminally produced ANG II. J Physiol Renal Physiol 280: F524 F529, 2001. Palade GE. Secretory granules in the atrial myocardium. Anat Rec 139: 262, 1961. Palkovits M, Eskay RL, and Antoni FA. Atrial natriuretic peptide in the median eminence is of paraventricular nucleus origin. Neuroendocrinology 46: 542544, 1987. Parkes DG and May CN. Hormones and the Heart in Health and Disease. Totowa, NJ: Humana, 1999, p. 39. Pedersen RC, Brownie AC, and Ling N. Proadrenocorticotropinderived peptides: coordinate action on adrenal steroidogenesis. Science 206: 1044 1045, Perez SE, Silva-Netto CR, Saad WA, Camargo LA, and Antunes-Rodrigues J. Interaction between cholinergic and osmolar stimulation of the lateral hypothalamic area LHA ; on sodium and potassium excretion. Physiol Behav 32: 191194, 1984. Peters GR, Ward NJ, Antal EG, Lai PY, and Demaar EW. Diuretic action in man of a selective kappa opioid agonist: U-62, 066E. J Pharmacol Exp Ther 240: 128 131, Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev Physiol 49: 413 435, Phillips MI, Heininger F, and Toffolo S. The role of brain angiotensin in thirst and AVP release induced by hemorrhage. Regul Pept 66: 311, 1996. Phillips MI and Kimura B. Brain angiotensin in the developing spontaneously hypertensive rat. J Hypertens 6: 607 612, Phillips MI, Shen L, Richards EM, and Raizada MK. Immunohistochemical mapping of angiotensin AT1 receptors in the brain. Regul Pept 44: 95107, 1993. Phillips MI and Sumners C. Angiotensin II in central nervous system physiology. Regul Pept 78: 111, 1998. Phillips MI, Weyhenmeyer J, Felix D, Ganten D, and Hoffman WE. Evidence for an endogenous brain renin-angiotensin system. Federation Proc 38: 2260 2266, Picanco-Diniz DW and Antunes-Rodrigues J. Substance P in jected into the medial preoptic area inhibits sodium, potassium and water urinary excretion. Putative modulation of the cholinergic system. Braz J Med Biol Res 22: 895 899, Picanco-Diniz DW, Ribeiro-Oliveira G, Favaretto AL, Gut kowska J, McCann SM, and Antunes-Rodrigues J. Does plasma ANP participate in natriuresis induced by alpha-MSH? Braz J Med Biol Res 30: 459 463, Porter JC, Sissom JF, Arita J, and Reymond MJ. Hypothalamic-hypophysial vasculature and its relationship to secretory cells of the hypothalamus and pituitary gland. Vitam Horm 40: 145174, 1983. Potts JT. Neural circuits controlling cardiorespiratory responses: baroreceptor and somatic afferents in the nucleus tractus solitarius. Clin Exp Pharmacol Physiol 29: 103111, 2002. Puryear R, Rigatto KV, Amico JA, and Morris M. Enhanced salt intake in oxytocin deficient mice. Exp Neurol 171: 323328, 2001. Puyo AM, Vatta MS, Donoso AS, Bianciotti LG, and Fernandez BE. Central natriuretic peptides regulation of peripheral atrial natriuretic factor release. Regul Pept 90: 9399, 2000. Qualy JM and Westfall TC. Release of norepinephrine from the paraventricular hypothalamic nucleus of hypertensive rats. J Physiol Regul Integr Comp Physiol 254: R993R1003, 1988. Quirion R, Dalpe M, and Dam TV. Characterization and distribution of receptors for the atrial natriuretic peptides in mammalian brain. Proc Natl Acad Sci USA 83: 174 178, Quirion R, Dalpe M, and Lean AD. Characterization, distribution, and plasticity of atrial natriuretic factor binding sites in brain. Can J Physiol Pharmacol 66: 280 287, Physiol Rev VOL 416. Quirion R, Dalpe M, Lean AD, Gutkowska J, Cantin M, and Genest J. Atrial natriuretic factor ANF ; binding sites in brain and related structures. Peptides 6: 11671172, 1984. Rauch AL, Callahan MF, Buckalew VM Jr, and Morris M. Regulation of plasma atrial natriuretic peptide by the central nervous system. J Physiol Regul Integr Comp Physiol 258: R531 R535, 1990. 418. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P, and Llorens-Cortes C. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci USA 96: 1341513420, 1999. Reaux A, Fournie-Zaluski MC, and Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 12: 157162, 2001. Rebsamen MC, Church DJ, Morabito D, Vallotton MB, and Lang U. Role of cAMP and calcium influx in endothelin-1-induced ANP release in rat cardiomyocytes. J Physiol Heart Circ Physiol 273: H922H931, 1997. 421. Reis LC, Ramalho MJ, and Antunes-Rodrigues J. Participation of the median raphe nucleus and central serotoninergic pathways in the control of water electrolyte excretion. Braz J Med Biol Res 24: 847 854, Reis LC, Ramalho MJ, Favareto ALV, Gutkowska J, McCann SM, and Antunes-Rodrigues J. Participation or the ascending serotonergic system in the stimulation of atrial natriuretic peptide release. Proc Natl Acad Sci USA 91: 1202212026, 1994. Renaud LP. CNS pathways mediating cardiovascular regulation of vasopressin. Clin Exp Pharmacol Physiol 23: 157160, 1996. Renaud LP and Bourque CW. Neurophysiology and neuropharmacology of hypothalamic magnocellular neurons secreting vasopressin and oxytocin. Prog Neurobiol 36: 131169, 1991. Rettig R and Johnson AK. Aortic baroreceptor deafferentation diminishes saline-induced drinking in rats. Brain Res 370: 29 37, Richard D and Bourque CW. Atrial natriuretic peptide modulates synaptic transmission from osmoreceptor afferents to the supraoptic nucleus. J Neurosci 16: 7526 7532, Riley PR, Flint AP, Abayasekara DR, and Stewart HJ. Structure and expression of an ovine endometrial oxytocin receptor cDNA. J Mol Endocrinol 15: 195202, 1995. Roberts MM, Robinson AG, Fitzsimmons MD, Grant F, Lee WS, and Hoffman GE. c-fos expression in vasopressin and oxytocin neurons reveals functional heterogeneity within magnocellular neurons. Neuroendocrinology 57: 388 400, Robertson GL, Shelton RL, and Athar S. The osmoregulation of vasopressin. Kidney Int 10: 2537, 1976. Robinson AG, Roberts MM, Evron WA, Verbalis JG, and Sherman TG. Hyponatremia in rats induces downregulation of vasopressin synthesis. J Clin Invest 86: 10231029, 1990. Rocha MJ, Beltz TG, Dornelles RC, Johnson AK, and Franci CR. Anteroventral third ventricle AV3V ; lesions alter c-fos expression induced by salt loading. Brain Res 829: 197200, 1999. Rocha MJ, Franci CR, and Antunes-Rodrigues J. Participation of cholinergic and adrenergic synapses of the medial septal area MAS ; in the natriuretic and kaliuretic responses to intraventricular hypertonic saline NaCl ; . Physiol Behav 41: 2328, 1985. Rodriguez Lopez P, Ehlerding A, Leonhardt S, Jarry H, and Uttke W. Effects of angiotensin II and atrial natriuretic peptide on LH release are exerted in the preoptic area: possible involvement of gamma-aminobutyric acid GABA ; . Exp Clin Endocrinol 101: 350 355, Rosenthal W, Seibold A, Antaramian A, Lonergan M, Arthus MF, Hendy GN, Birnbaumer M, and Bichet DG. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature 359: 233235, 1992. Rossi NF. Effect of endothelin 3 on vasopressin release in vitro and water excretion in vivo in Long Evans rats. J Physiol 461: 501511, 1993. Rossi NF. Cation channel mechanisms in endothelin 3-induced vasopressin secretion by rat hypothalamo-neurohypophysial explants. J Physiol Endocrinol Metab 268: E467E475, 1995. 437. Rossi NF and Chen H. PVN lesions prevent the endothelin 1-in prv.
18. All of the following statements about the use of Lithium are true EXCEPT: a ; It is used as mood stabilizer in manic-depressive illness. b ; It is excreted by the kidneys. c ; It replaces Na in the nerve cell and interferes with the transportation of nerve impulses. d ; It is more beneficial than neuroleptics such as Thorazine and Jaldol in treating acute manic symptoms. 19. Therapeutic index for Lithium is: a ; 0.2 - 2.2 MEQ L b ; 0.5 - 1.5 MEQ L c ; 1.5 - 3.5 MEQ L d ; 1.5 - 2.5 MEQ L.

Haldol review 5IIrgIc-typereaCbOnsQncIudingbronchialasthma ; inceftainsusceptibleindividuals, especiallyin thoaewhohsvehyvfty. !nlc, rne.t, ionfcrPat * ifs: tasksordr$vlng maybeinspatre Alcohol and hypotensior w !ntwecftcris: Patients receiving llthkim plus haloperidol should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear. As wIth other antipeychotic agents it should be noted that HALDOL may be capable of pc * andalcohoL C.rc * iopenssis & * aagsneeb andlmpkment olFerlifity: No mutagenic potential of haloperidol decanoatewsa found in theAmes SalmOnellarvilcroeOmal activation assay. Carcinoosnicity studies using oral haloperidol were conducted in Wistar rats dosed at up to mojkgdellyfor24 months ; andlnAltsno SwIss mice doeed at upto5mojkg daily for l8months ; . Intherat reducing thenumberOf ratsatrisk fordomloplngtumors. However, the study In Jges dose male and female groups these animals did not have aeater incidence of tumors then control animals Therefor although not ophin * this study does suggest the absence of a haloperidol related increase in the incidence of neoplesla in rats at doses up to 20 times theUsualdaily humwdosoforchronlcorreslstant patients. In female mlceat5and20times the highest initial daily dose for chronic or resistant patients there was a statistically significant increese in mammary gland neoplasla and total tumor incidence; at 20 times the sense daly dose there was a statistically signifIcant increase in pituitary gland neoplasla. In male mic no statistically significant differences in incidences of total tumors or specific tumor types were noted Antipsychotic drugs elevate prolactin levels the elevation persists duflng chronic admirsistra. tiols. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolacbndependentInvftrc afactorof contemplated in patient with a previously detected breast cancer. Although disturbances such as galactorthea. wsenorrtsea, gynecomastia. and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplesms has been build in rodents after chronic administration of entipsychotic drugs Neltherdllnlcal studies norepidemlologic studlesconductedtodate, however, haveshown an association between chronic adminIstration of these drugs and mammary tumongenes the tobeconclusiveat this bins t a, Pregnancy: Pregnancy Category C Safe use in pregnancy or in women likely to the fetos MirsingMothar Infants should not be nursedduring drug treatment. Pediatric List Controlled trials to establish the safety and effectiveness of intramuscular administration in children havenot been conducted Adverse Reactions: Adverse reactions following the administration of HALDOL haloperidol ; Decanoate are those of HALDOL. Since vast experience has accumulated with HALDOL, the adverse reactions are reported for that compound as well as for HALDOL Decanoate As with eN e1jectabIemedIcabons local tissuereechions havebeen reported with HALDOL Decanoats c4vsB'fects Extrapymmb-iat Reections-Neuromuscular extrapyramidal ; reacbons have been reported frequently. often during the first few days of treatment. Generally they involved. Assets Current assets: Cash and cash equivalents Accounts receivable including receivables from related parties of 9 in 2002 and , 826 in 2001 ; Other receivables Inventories Deferred income taxes Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Deferred income taxes Marketable securities Other assets Total assets Liabilities and Shareholders' Equity Current liabilities: Accounts payable Accrued liabilities including accrued liabilities to related parties of 4 and 4 in 2002 and 2001, respectively ; Current portion of long-term debt Current portion of capital lease obligations Income taxes payable Total current liabilities Long-term debt Long-term portion of capital lease obligations Other liabilities Mandatory redeemable convertible preferred stock Commitments & Contingencies Shareholders' equity: Preferred stock, par value per share; authorized 2, 000, 000 shares; none issued Common stock, $.01 par value per share; authorized 100, 000, 000; issued 43, 792, 170 and 42, 333, 524 in 2002 and 2001, respectively Additional paid-in capital Additional paid-in capital warrants Retained earnings Accumulated other comprehensive income Treasury stock at cost: 186, 932 and 176, 332 in 2002 and 2001, respectively Total shareholders' equity Total liabilities and shareholders' equity and fluoxetine. Examination figs. 11-1 and 11-2 ; . The SF 88 is, like most medical documentation, a legal document. Entries on the form must be legible. If you make a typographical or clerical error, correct the entry by drawing a single line through the erroneous entry, initialing above the error, and making the corrected entry in the same block. If space is not available in that block, make the corrected entry in block 42 identifying the erroneous entry by number ; . Chapter 16 of the MANMED provides specific details on information for each block to complete this form properly. Stamps are used routinely by many naval medical facilities to incorporate routine information or data onto medical documents, as illustrated in blocks 50 and 73 of figures 11-1 and 11-2. The use of stamps must, however, be in accordance with physical examination directives and the MANMED. REPORT OF MEDICAL HISTORY, SF 93 The purpose of Standard Form SF ; 93, Report of Medical History, is to provide a complete personal medical history and to serve as a source of information that supplements information reported on the SF 88. The SF 93 provides a current, concise, and comprehensive record of a service member's personal medical history before entering the service and any subsequent changes in the member's medical status. After the military entrance examination, any subsequent medical examinations that require the use of the SF 88 will also require an SF 93 completed. Any medical information entered by patients on the SF 93 is made only to document changes in medical history since their last physical examination. If no changes have occurred since the previous SF 93 was generated, the examiner should enter "no significant interval history" in block 25. When you prepare the SF 93, complete items 1 through 7 in the same manner as you did the SF 88 fig. 11-3 ; . This information can be handwritten or typed. Inform examinees that they are responsible for completing items 8 through 25 figs. 11-3 and 11-4 ; . Item 8 should contain a handwritten statement from examinees regarding their present state of health and any medications they may be taking. Items 9 through 24 are checked either "yes, " "no, " or "don't know" by the examinees. Assist examinees by explaining unfamiliar medical terminology that appears on these items. Helping them complete the form will ensure an accurate accounting of the member's medical history. Keep in mind that the SF 93 is information of.

Haldol online Glucose Level between 60 and 250: 1. Check for signs of associated medical conditions, trauma or toxic ingestion or overdose, CVA, or hypoxia as the cause of altered level of consciousness and follow the appropriate protocol. 2. Establish IV 0.9% NS at 100 ml hr. 3. Consider use of oral glucose, 50% DEXTROSE 25 gm IVP, NALOXONE Narcan ; , GLUCAGON or other treatment interventions. Glucose Level above 250 or signs of dehydration: 1. Start IV 0.9% NS at 250 ml hr and draw blood. Give 500 ml bolus if SBP 90 mmHg. 2. Transport. 3. Check for signs of other medical conditions, trauma or ingestion as cause of altered LOC. Consider the possibility of painless silent ; MI if patient is cool and diaphoretic even without complaint of chest pain. 4. Contact On-Line Medical Direction and paroxetine. Morphine for pain and shortness of breath ; Morphine is an opioid naturally occurring narcotic ; . It is considered the `gold standard' drug for controlling pain and can be very helpful for relieving shortness of breath. Two great advantages are there is no limit to the amount that can be given and it can be taken by any route. For those people with chronic or constant pain, it is important for them to take their pain reliever regularly not just "when needed". Because long-term pain affects the body different than short-term or acute pain, it requires that the medicine be given on schedule as in every four hours to keep ahead of the pain. And, when pain occurs between scheduled doses, additional drug should be taken for this "breakthrough" pain. Patients will not become "addicted" to the narcotic. All narcotics have side-effects. Constipation requires stimulant laxatives e.g. senokot ; . Nausea and sedation are common initially, but these tend to improve after a few days. For people who have been in pain a long time, as their pain is relieved with the morphine it is normal to be sleepy for a few days initially; if this doesn't improve, there are different medications which can help. Muscle twitching can occasionally occur but if this not bothersome, there is no need for treating it. Confusion is sometimes seen in the beginning this is not an allergy ; but can be treated with a drug such as Ualdol below ; . If a person is truly allergic to morphine a rare event ; , other narcotics such as Dilaudid [hydromorphone] or Percocet [oxycodone] or methadone can be used instead. Compazine [prochlorperazine] for nausea & vomiting ; This is an excellent drug for controlling nausea vomiting. It is more effective and has less sedation and risk of confusion than does Phenergan [promethazine]. Reglan [metoclopramide] for nausea & vomiting, or reflux ; Reglan has many useful purposes: nausea vomiting, reflux heartburn ; , constipation promotes small bowel movement ; . It can rarely cause someone to become rigid in their muscles; reducing the dose is usually all that needs to be done. Experimental Trials. In preparation for the experimental trials, subjects were instructed to perform a similar training volume for the 3 d before each test and to avoid vigorous exercise for 24 h before testing. In addition, they were instructed to report to the laboratory after maintaining a standard mixed diet for 2 d before each test session. Food records were kept before the first experimental test session, and this diet was replicated for the 2-d period before subsequent trials. Subjects were instructed not to consume alcohol, caffeine, or nonprescription drugs the day before and on the day of testing. On arrival at the laboratory, subjects completed a 24-h history form to assess compliance with pretest instructions. Subjects reported in a normally hydrated state. Euhydration was accomplished by instructing subjects to drink liberally the day before and to drink one 237-ml glass of water 1 h before testing. Urine specific gravity was measured with a refractometer to ensure that urine specimens provided by subjects before testing were 1.021 2 ; . In almost all cases, subjects had fasted overnight before each experimental session. For 4 subjects, however, the postprandial state was standardized to be a minimum of at least 3 h after the ingestion of a small meal or CHO drink. Before cycling, maximal voluntary and electrically evoked isometric contractile properties of the right knee-extensor muscles were measured. After the baseline strength measures, a Teflon catheter was inserted into an antecubital vein. Subjects drank the first aliquot of the experimental test beverage, and the initial blood sample was drawn. Ten minutes later, the second aliquot of the beverage was ingested and subjects began the cycling protocol. The subjects cycled continuously for a total of 135 min, alternating the exercise intensity between 60% and 75% VO2max every 15 min for the first 120 min and trazodone.

Simpson K.N. and Lynch S.R. Cost savings from the use of antenatal steroids to prevent respiratory distress syndrome and related conditions in premature infants. J Obstet Gynecol 1995; 173: 316-21. Simpson, K. N., A. Biddle, NR Rabinivich. A Model for Estimating the Impact of Changes in Children's Vaccines. J Pub Hlth 1995 85: 12 Luce, B.R. and K.N. Simpson. Methods of Cost Effectiveness Research: Areas of Consensus and Debate. Clinical Therapeutics 1995 17: 1 Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, Nicola R Zellinger J and Simpson KN. Health Care Expenditures for Tuberculosis in the United States. Arch Intern Med 1995 155 1595-1600. Simpson K.N. Problems and Perspectives on the Use of Decision-Analysis Models for Prostate Cancer. J Urology 1994, 152; 1888-1893. Simpson K.N. Outcomes research in prostate cancer- Editorial. J Urol 1994, 152; 1865. Knechten, H nach KN Simpson. Argumente Fur die Kombination von Azidothymidin und Zalcitabin. Springer: Belage fur Internisten, pp 17-18, 1994. Simpson, K., F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. Cost Effectiveness of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients with CD4 counts 300 per mm3 in Five European Countries. PharmacoEconomics 1994, 6 ; 6; 553-562. LaVallee, RW and Simpson, KN. Working for the Government: PAs in the Department of Veterans Affairs. J Acad Physician Assist, 1993, 6: 2 Kaluzny, AD, CP McLaughlin, and KN Simpson. Applying Total Quality Management Concepts in Public Health Organization. Public Health Reports, 1992, 257-264. Simpson, K.N., G. Stoodt, S.G. Sherman, and P. Rochester. Strategic Planning for Public Health: Cancer Control in North Carolina. Evaluation and Program Planning: Int J, 1992, Vol 15, pp 383-393. DesHarnais, SI and KN Simpson. Indices for Monitoring Hospital Outcomes in Developed Countries. Health Policy, 1992, Vol 21, pp 1-15. Simpson, K.N. and Lyle B. Snider. Informing Mammography Coverage Debate: Results of Meta Analysis, Computer Modeling, and Issue Analysis. Intl J Tech Ass Hlth Care, 1991, Vol 7, No. 4, pp 616-631. Simpson, KN, AD Kaluzny, and CP McLaughlin. Total Quality and the Management of Laboratories. Clin Lab mgt Rev, 1991, pp 448-462. Simpson, K.N. and J.E. Veney, "National Indicators for Health for All, " Soc Indicators Res, Oct. 20, 1988, pp. 533-548. NDA No. 50-425 20-479 11-245 Supp No. SLR 004 SLR 002 SLR 029 SLR 005 SLR 010 SLR 028 SLR 028 SLR 005 SLR 002 SLR 039 SLR 001 SLR 022 SLR 001 SLR 015 SLR 002 SLR 009 SLR 007 SLR 008 SLR 041 SLR 021 SLR 022 SLR 029 SLR 033 SLR 075 SLR 065 SLR 066 SLR 043 SLR 016 SLR 037 SLR 038 SLR 005 SLR 012 SLR 038 SLR 055 SLR 038 SLR 069 SLR 073 SLR 013 Trade Name GARAMYCIN GASTROCROM GASTROGRAFIN GAVISCON GEMZAR GENOTROPIN GENOTROPIN PRESERVATIVE FREE GEREF GLUCAGEN GLUCAGON GLUCAGON GLUCOPHAGE GLUCOPHAGE XR GLUCOTROL GLUCOVANCE GLYNASE GOLYTELY GOLYTELY GRISACTIN GYNE-LOTRIMIN GYNE-LOTRIMIN H.P. ACTHAR GEL HALCION HALDOL HALDOL HALDOL HALDOL HALOG HALOTESTIN HALOTESTIN HELIDAC HEMABATE HEPARIN LOCK FLUSH HEPARIN SODIUM HEPARIN SODIUM HEPARIN SODIUM PRESERVATIVE FREE HEPARIN SODIUM PRESERVATIVE FREE HERPLEX Active Ingredient GENTAMYCIN SULFATE CROMOLYN SODIUM DIATRIZOATE MEGLUMINE ALUMINUM HYDROXIDE MAGNESIUM TRISILICATE GEMCITABINE HCL SOMATROPIN RDNA ORIGIN ; FOR INJECTION SOMATROPIN RDNA ORIGIN ; FOR INJECTION SERMORELIN ACETATE GLUCAGON RDNA ; GLUCAGON HYDROCHLORIDE GLUCAGON FOR INJECTION RDNA ORIGIN ; 1mg METFORMIN HCL METFORMIN HCL GLIPIZIDE METFORMIN HCL GLYBURIDE GLYBURIDE POLYETHYLENE GLYCOL 3350 ELECTROLYTES POLYETHYLENE GLYCOL 3350 ELECTROLYTES GRISEOFULVIN, MICROCRYSTALLINE CLOTRIMAZOLE CORTICOTROPIN TRIAZOLAM HALOPERIDOL HALOPERIDOL LACTATE HALOPERIDOL LACTATE HALOPERIDOL DECANOATE HALCINONIDE FLUOXYMESTERONE FLUOXYMESTERONE BISMUTH SUBSALICYLATE METRONIDAZOLE TETR CARBOPROST TROMETHAMINE HEPARIN SODIUM HEPARIN SODIUM HEPARIN SODIUM HEPARIN SODIUM HEPARIN SODIUM IDOXURIDINE Approval Date 29-Jul-97 8-Feb-00 5-Aug-94 and celexa. In the non-psychotropic patient they are used to treat tourette's or tic disorders: haldol haloperidol ; , orap pimozide ; , stelazine trifluoperazine ; , thorazine chlorpromazine ; , risperdol resperidone ; , zyprexa olanzapine. This is widely assumed to be crucial and is often cited as the most important reason why individuals with schizophrenia and bipolar disorder fail to take their medications. Studies, however, suggest that it is a much less important reason than the three reasons discussed above. In one review, only 1 out of 9 studies found a significant association between side effects and medication adherence in individuals with schizophrenia Lacro et al., op cit. ; . The comparative lack of importance of side effects in determining medication adherence is also suggested by studies comparing medication adherence in individuals taking first-generation antipsychotics e.g., haloperidol Hhaldol ; , which often have side effects bothersome to patients, and second-generation antipsychotics e.g., olanzapine Zyprexa ; , which have far fewer such side effects. Studies comparing adherence rates between first- and second-generation antipsychotics have reported them to be virtually identical and zyprexa.

Riehemann, & Sag, 1995 ; , to our best knowledge LOGON is the first system to implement end-to-end MRS-based translation. Broadly speaking, MRS is a flat, event-based neoDavidsonian ; framework for computational semantics that facilitates underspecification of both scope relations1 and generalization over classes of predicates e.g. two-place temporal relations corresponding to distinct lexical prepositions: `in May' vs. `on Monday'; see 5 below ; , thus enabling MT components to defer the resolution of ambiguity and supporting flexible experimentation with `moving' distinctions around between the analysis, transfer, and generation phases. Furthermore, the abstraction from SL and TL surface properties enforced in our semantic transfer approach facilitates a novel combination of diverse grammatical frameworks, viz. lfg for Norwegian analysis and hpsg for English generation. While an in-depth introduction to MRS for MT ; is beyond the scope of this note but see references cited above ; , Figure 1 presents an example semantics for a simplified example from the LOGON corpus. The truth-conditional core is captured as a flat multiset or `bag' ; of elementary predications EPs ; , combined with generalized quantifiers and designated handle variables to account for scopal relations. The bag of EPs, often termed the RELS set, is complemented by the handle of the top-scoping EP and a set of handle constraints or HCONS ; recording restrictions on scope relations contributed by the syntax. Figure 2 presents the main components of the LOGON prototype, where all component communication is in terms of sets of MRSs and, thus, can easily be managed in a distributed and potentially ; parallel client server set-up. Both the analysis and generation grammars `publish' their interface to transfer--i.e. the inventory and synopsis of semantic predicates-- in the form of a Semantic Interface specification `SEM-I' ; , such that transfer can operate without knowledge about grammar internals. In practical terms SEM-Is are an important. To investigate the role of the prostatic tissue in the increase in IUP, the IUP responses to PHE 30 g kg i.v. ; in "prostate-lacking" rats were compared with those in "prostate-intact" rats as follows. Prostate-Ablated Rat. After all preparations for the measurement of IUP had been made, both dorsal and ventral prostatic tissues were partially ablated from the urethral wall by gentle rubbing with a cotton bud. The IUP responses to PHE in these rats were compared with those in prostate-intact male rats. During this experiment, rats that exhibited bleeding in the area of ablation were excluded. Female Rats. The IUP response to PHE at the proximal urethra between vesicourethral junction and distal urethra under the pubic bone ; was also measured in 9- to 10-week-old female Sprague-Dawley rats Japan SLC Inc., Shizuoka, Japan ; weighing 200 to 250 g and compared with those in prostate-intact male rats. Castrated Rat. Castration was performed on 5-week-old male rats. Four weeks after the castration, the IUP response to PHE 30 g kg ; was measured by the same procedure as described above, and the results were compared with those for sham-operated rats. Both ventral and dorsal prostatic weights were also determined after the measurement of urethral pressure responses to PHE had been completed. The increase in IUP responses in prostate-ablated and female rats were compared with those in prostate-intact male rats, and responses and prostatic weights in castrated rats were compared with those in sham-operated male rats using Student's t test and risperdal.
Expected to treatment respond with # HALDOL tohaloperidol? Yes, in many cases patients who have not shown satisfactory improvement with other major tranquilizers have responded well to treatment with HALDOL haloperidol. The Health Insurance Portability and Accountability Act of 1996 HIPAA ; is a Federal law that offers limited Federal protections for health coverage availability and continuity to people who lose employer group coverage. If you leave the FEHB Program, we will give you a Certificate of Group Health Plan Coverage that indicates how long you have been enrolled with us. You can use this certificate when getting health insurance or other health care coverage. Your new plan must reduce or eliminate waiting periods, limitations or exclusions for healthrelated conditions based on the information in the certificate, as long as you enroll within 63 days of losing coverage under this Plan. If you have been enrolled with us for less than 12 months, but were previously enrolled in other FEHB plans, you may also request a certificate from those plans. For more information, get OPM pamphlet RI 79-27, Temporary Continuation of Coverage TCC ; under the FEHB Program. See also the FEHB Web site opm.gov insure health refer to the "TCC and HIPAA" frequently asked questions. These highlight HIPAA rules, such as the requirement that Federal employees must exhaust any TCC eligibility as one condition for guaranteed access to individual health coverage under HIPAA and have information about Federal and State agencies you can contact for more information and zyban.

Fiablperdol decanoate showed an increase in incidence of resorption, fetal mortaldy, and pup mortatity No fetal abnormalities wereobserved Deft palate has been observed in mice given oral halOpereid at 15 times the usual manimum human dose. Cleft palate in mice appearsto be a non-specific response to stress or nutntional imbalance as weflasto a variety of drugs. andthere is no evidericeto retatethis phenomenon to predictable human riskfor most ofthese agents. There are no adequate and well-controlled studies in pregnantwomen There are reports, however, oftwo cases of limb malformations observed following maternal use of HALDOL along with other drugs which have suspected teratugenic potential dunng the first trimester of prngnancy Causal refabonstips were not established in either case. Since such expenerice does not exclude the possifality offetat damagedue to HALDOL, HALDOL Decanoate shoubl be used during pregnancy or in women likely to become pregnant only if the beneht clearly ustities a potential risk to the fetus Nursing MOIhecu Since haloperetol is eocreted in hianan breast milk, infants shouft not be nursed during drug treatment with HALDOL Decanoafe Ped, atricUse Safety and eftechveness of HALDOL Decanoate in ctiklren have not been established. Adverse Reactisna: AdversereachonsfoRowing theadministraton 0fHALDOL halopendot ; Decanoate arethoseof HALDOL. Since vast experience has accumulated with HALDOL, the adverse reactions are reported for that compound as well as for HALDOL Decanoate. As with all injectable medications. local tissue reactions have been reported with HALDOL Decanoate ads Effects Extrap, ramidal Reactions-Neteomuscutar ; extrapyrarnidal ; reactions during the administration of HALDOL have been rorted frequently, often dseing the test few days of treatment These have atso been reported wdh HALDOL Decanoate In most patents, these reactrens involved Parkusson-hke symptoms wfach, when first observed, were usually mdii to moderately severe and usually reversible. Other types of neuromuscular reactions motor restlessness, dystonio, akattisia, hyperreffexia, opisthotonos, ocutogync crises ; have been reported far less frequently, but were often more severe. Severe extrapyramelal reactions have been reported to occur at relatively low doses Generally the occurrence and severity of most exfrapyramkial symptoms are dose-related since they occur at relatively blgh doses and have been shown to disappear or become less severe when the dose is reduced. Administration of anfiparkinson drugs such as benotropine mesylate US.Por tnhexyphenefyt hydrocflorete US.P may be required for control of such reactions. C shouki be noted that persistent extrapyramelal reactions have been reported and thatthe drug may have to be discontinued in such cases Withdrawal Emergent t * urnlogical Signs-Generally, pahents receiving short-term therapy enpenence no problems wdh abrupt discontinuation of antipsychofic drugs However, some patients on maintenance treatment expenence transient dyskinietic signs after abruptwithdrawal. In certain ofthese casesthedyskinetic movements are indistinguishable from the syndrome descnbed below under "brdive Dyskinesia" except for duration Although the long acting properties of HALDOL Decanoate provele gradual withdrawal, it is not known whether gradual withdrawal of antipsychotic drugs will reduce the rate of occurrence of withdrawal emergent neurological signs. Tardwe Dydones, a-As with all anbpsychohc agents HALDOL has been associated with persistent dyskinesias l# rdive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may apoear in some pabents on long-term therapy wdh HALDOL Decanoate or may occur after drug therapy has been discontinued. The risk appears to be greater in elderly patients on high-dose therapy, especially females. The symptoms are persistent and in some patients appear irreversible. The syndrome is chacterized by rhythmal involuntary movements of tongue, face, mouth, or law eg., protrusion of tongue, putting of cheeks, puckenng of mouth, chewing movements ; Sometimesthese may be accompanied by involuntary movements of extremities. There is no known effective treatment for tardive dyskinesia; antipartrinson agents usually do not atleviafe the symptoms of tfas syndrome. If is suggested that all anitipsychotic agents be discontinued if these symptoms appear Shouki it be necessary to nonstitute treatment, or increase the dosage of the agent, or switch to a ddferent anfipsychofic agent, INs syrxleome may be masked. It has been reported that fine vermicular movement of the tongue may be an early sign of the syndrome and d the medication is stopped at that time the syndiome may n develop. Other CNS effects-Insomnia, restlessness, anxiety, iojphoria, agitation, drowsiness. depression, lethargy, headache, confusion, vertigo, grand mal seizures exacerbafion of psychotic symptoms induding hallucinations, and catatonic-like behavioral states wl'uch may be responsive to drug withdrawal andftir treatment with anticholinergic drugs Boef as a Whole As with other neuroleptic drugs, a symptom complex sometimes referred to as neuroleptic malignant syndrome ; NMS ; has been reported with HALDOL Cardinal features of NMS are hyperpyreoia, musde ngdity, altered mental status ; including catatonic signs ; , and evidence of autonomic instalotity irregular pulse or blood oressiwef Additional signs may indude elevated CPK, myoglotanufla ; rhabdomyblysis ; , and acute renal failure. NMS is potentially fatal, requires intensive symptomatic treatment and discontinuation of neuroleptic treatment Hyperpyrenia and heat stroke, not associated with the above symptom complex, have also been reported with HALDOL. CardiovascularEftects Tachycardia, hypolension, hypertension and ECGchanges. Hemato ogic Etfects. Reports have appeared citing the occurrence of mAt and usually transient leukopenia and leukocytosis, minimal decreases in red blood cell counts, anemia, or a tendency toward lymphomonocytosis. Agranulocytosis has rarefy been reported to have occurred with the use of HALDOL, and then only in association with other medication. LiverEffects Impaired liver function and or laundice have been reported. Oei'matolog, c Rextions Maculopapular and aa'iioform skin reactions and isolated cases of photosensitivity and loss of hair. Endocrine Disorders Lactation, breast engorgement, mastala, menstrual irregulanties, gynecomastia, impolence, increased libido, hyperglycemia, hypoglycemia and hyponatremia GastrointestinalEffects. Anorexia, constipahon, diarrhea, hypersalivation, dyspepsia, nausea and vomiting Au.tonomicRextions Dry mouth, blurred vision, urinary retention and diaphoresis RespiratoryEffects Laryngospasm, bronchospasm and increased depth of respiraflon Othet Cases of sudden and unexpected death have been reported in association with the administration of HALDOL The nature of the evidence makes it impossible to determine definitively what role, if any, HALDOL played in the outcome of the reported cases The possitality that HALDOL caused death cannot, of course, beexcluded, but it is to kept in mind that sudden and unexpected death may occur in psychotic patients when they go untreated or when they are treated with other neuroleptic drugs DOSAGE AND ADMINISTRATION HALDOL ; haloperidol ; Decanoate should be administered by deep intramuscular infection into the gluteal region A 2" long 21 gauge needle is recommended The maximum volume per int site shouki not exceed 3 ml The recommended interval between doses is 4 weeks DO NOTADMINISTER INTRAVENOUSLY HALDOL Decanoate is intended for use in chronic psychotic patients who require prolonged parenteral neurolepfic therapy These patents shouki be previously statalized on antipsychotic medication before conselering a conversion to Hakiol Decanoate Furthermore, it is recommended that pahents bong considered for Halool Decanoate therapy be initially converted to oral halopendol from whatever other neuroleptic they are taking ; in order to exclude the possibility of an unexpected adverse sensitMty to haloperelol Close clinical supervision is required during the initial period of dose adlustment in order to minimizethe risk ofoverdosage or reappearance of psychotic symptoms before the next injection. Dunng dose adlustment is episodes of exacerbation of psychotic symptoms, Hakiol Decanoate therapy can be supplemented with short-acting forms of halopendol The starling dose of Hablol Decanoate stiouki be based on the patient's clinical history, physical condition, and response to previous antipsychelic therapy The preferred approach to determining the minimum effective dose is to begin with lower initial doses and to adjust the dose upward as needed C is recommended that the inihal dose of Hald9l Decanoate be 1O-l5timesthe evious daily dose in oral halopendol equivalents, butnomorethan a maximum initial dose of 100 mg 2 ml ; l'Iakiol Decanoate has been effectively administered at monthly intervals in several clinical studies However. variation in patient response may dictate a need for adtustment ofthe dosing intervalas well as the dose. Lower initial doses and more gradual adlustment are recommended for elderly or debilitated patients Clinical experience with HALDOL Decanoale at doses greater than 300 rrig 6 ml ; per month has been limited Full directions for use should be read before mlntsterIng or prescribing. For information on symptoms and treatmentofoverdosage, seefull prescribng information.

Nutraceuticals and Functional Foods are one of the hottest categories in foods and beverages. In fact these foods and ingredients are the fastest growing segment in the U.S. Food Industry and one of the top ten trends to watch and work on for the Millennium according to Food Technology Vol. 53, no 8 ; . Both big and small food manufacturers are producing nutraceuticals and trying to manufacture and market that food or ingredient that may provide a health benefit beyond that of basic nutrition. Why the craze for these foods? In America there appears to be a mainstream interest in nutrition and health and a recognition of food as medicine. People are taking more responsibility for their health.the trend is for healthy foods and promoting health and wellness. Consumers buying into the nutraceutical market are not only people trying to feel good and improve their health, but middle aged people trying to keep up with the younger generation, college students trying to gain a competitive edge, soccer moms teaching their children a healthy lifestyle and working moms seeking added energy. Or there are those that wish to reduce the risk of certain diseases by consuming specific foods, i.e. dairy foods for osteoporosis and soy protein or plant sterols for cardiovascular health. Nutraceuticals, or now what is being dubbed functional foods, are any ingredient or food supported by some degree of scientific evidence hopefully ; that confers healthful benefits. Fortified foods also fall into the nutraceutical functional food category. Foods may be fortified with vitamins, minerals and antioxidants. Vitamin D fortified milk may be one of the earliest functional foods. Typical functional foods include juice fortified with calcium and antioxidants, beverages to increase mental alertness and energy, high calcium yogurt and ice cream, hypervitaminized and energized teas, fructooligosaccharides inulin ; added as an ingredient to foods to improve calcium absorption, lower cholesterol and ensure a healthy intestinal tract, oat bran and a wide variety of herbal supplements echinacea, ginseng, ginkgo, garlic, St. John's wort, kava kava, etc ; . The functional foods marketplace has also found room for such innovative and creative foods like Heavenly Hemp Tortilla Chips, Almond Breeze beverage, Luna Bars of benefit to women, Silk Soymilk Creamer and a variety of beverages with promises to increase weight loss, healing, relaxation, stamina and energy, to name a few. Let's not forget dairy products and positive health see subsequent article ; . Most dairy products are high in calcium which reduce the risk of osteoporosis, hypertension, and colon cancer and may reduce the risk of cardiovascular disease and kidney stones. Dairy foods certainly can find an active role in the functional food category and improve one's health and well being. Here's to good health and wellbutrin.
Allergic-type reactionsWig bronchial asthma ; in certain susceptible individuals, especiallyin thosewhohaveas Infornatbii lbrPat * ifs: Mental andr physical ablitties required for hazardous tasks or driving may belenpaWed Alcohol shOtaldbeavOideddUe topossibieadctitiveeffects and hypotenslort interscticn& Patients receMng kIfum plus haloperidol should be monitored closely for early evidence of neurological toxicity and treelment discontinued promptly if such signs appeer. As with other antipsychotic agents, it should be noted that HALDOL may be capable of and alcohol. Carckiogenseia MsanesIs andlmpakmentolFertlllty: No mutagenic potential of haloperidol decanoate was found in theAmes SeIITtOneIIamicrOSOmal activation assay. Carcinogenicity studies using oral haloperidol were conducted in Wistar rats dosed at up to rn1cg daily for 24 months ; andln Aibino Swiss mice dosed at up to mgflcg daily for 18 months ; . Intherat reducing thenumberofratsat risk fordevelopinotumors. However, totheendof the study in tgh dose male and femalegroups these animals did not have agreater incidence of humors than control m&s Therebs though not optim this study does suggest the absence of a halopeddol related increase in the incidence of neoplasia in rats at doses up to 20 timestheusualdaily humandoeebrchronicorresistwt patients. In femalemiceat5 and2otimes the highest initial dally dose for chronic or resistant patients there was a statistically significant increase in mammary gland neoplasia and total tumorincidence; at 20 tImes the same daily dose there was a statistically significant increase in pituitary gland neoplasia. In male mica no statistically significant differences in incidences of total tumors or specific tumor types were notert Antipsychotic drugs elevate prolactin leve the elevation persists during chronic adrninistrahon. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependentin aitrc afactorofpotential knportance ifthe prescriptionof thesedrugsis contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrttea, amenorrhea, gynecomastia, arid lempotence have been reported the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs Neitherdinical studies norepidemiologic studiesconducted todate, however, haveshown an association between chronic administratiOn of these drugs and mammary tumorigenesis the availableevidence isconsidered toolenited tobeconclusiveat this time. L.isage in Pregnancy: Pregnancy Category C Safe use in pregnancy or in men lllely to useonlyifbenefftciee# yistffiespotentialhazardsto the fetus MirsingMofhers Intents should not be nUrseddUringdrUg treatment Pediatric t.Isac Controlled trials to establish the safety and effectiveness of intramuscular administration In cisidren havenot been conductect Adverse Reactions: Adverse reactions following the administration of HALDOL halopendol ; Decanoate are those of HALDOL, . Since vast experience has accumulated with HALDOL, the adverse reactions are reported for that compound as welt as for HALDOL Decanoata As with all lfljCthbletflediC5tiOflS, local tissuereactions havebeen reported with HALDOL Decanoete. as &iincts Extrapyrimkfe! Rsacfions-Neuromuscular extrapyramidal ; reactions have been reported frequently, often during the fret few days of treatment. Generally they involved ParkinsorWlle symptoms which when first observed were usually mild to moderately severe and usually reversibls Other typesof neuromuscular reectiona motor resdessness dystonie, akathiala, hyperrefleida, opisthotonos, octiogyric crises ; have been reported far less frequently but were often more severe. Severe extrapyramidal reactions have been reported at relatively low doses Generally, extrapyramidal symptoms are doee.related since they occur at relatively high doses and disappearor become less severe when thedoeeis reduced. Antiperkinson drugs may berequired. Persistent extrapyramidal reactions have been reported and the dru9 may have to be discontinued in such cases. 14 * IIdraW&EmSI'QerPt IteuroJogibe! Signs-Abrupt dsscontinuation of short-term antipeychotic therapyisgenerallyuneventfut However, some patierttson maintenance treatment experience transient dyalkinetic signs after abrupt withdrawal. In certain cases these are indIstingUishable from `IlordiveDyskinesia" exceptforduration. ft isunknown WtlethergradUal withdrawal wilt reduce the occurrence of these signs but until further evidence is available HALDOL should be gradually withdrawn lierdWe Dyskinesle-As with at antipsychotic agents HALDOL has been associated with persistent dyskinesias b'dive dyskinesia, a syndrome consisting of potentially Wreversit * involuntary, dyskinedc movements may appear in some patients on long-term therapy or may occur after drug therapy has been discontinued. The risk especiallyfemaiesThesymptoms are persistent and in some patients appear WreversibI The syndrome is characterized by rhythmical involuntary movements of tongt * facec mouth or aw sg, protrusion of tongt * puffing of cheek puckering of moutt chewing movements ; . Sometimes these may be amby involuntary movements of extremities and the trunk. There is no known effective treatment for tardive dyskinesi& antiparkinson agents usually do not allevIate the symptoms of this syndroms It is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch toe different auitipsychoticagertt, this syndrome may bemasked. ft hasbeen reported that fine vermicular movement of the tongue may be an early ssgn of tardive dyskinesia and if the medication is stopped at that time the full syndrome may not develop, laird!ve DYStOnia-lierdive dystonia, not associated with the above syndrome, has also been reportect lierdive dystonia is characterized by delayedonset ofchoreicordystonicmovements, isoften persistent, and has the potential of becoming irreversibls Other S BVects-lnsomnia, restlessness, anxiety, euphoria. Clozapine clozaril ; uses: refractory psychosis with failure from 2 classes 20mg day haldol ; for 6 weeks, or unable to tolerate other antipsychotics mechanism: d1 d2, d4 and 5ht-2a receptor antagonist; blocks a-1, achm, h1 sedation: 4-5 anticholinergic: 4-5 hypotension: 4 hypertension: 1-2 eps: low very low eps, no tardive dyskinesia useful for parkinsons + psychosis ; note: m4 agonist produces hypersalivation ; less common: hypertension, leukopenia, agranulocytosis 2-3% ; [weekly cbc for 6 months, than monthly], sz 1-2%, 5% over 600mg day ; hepatic metabolism cyp1a2 half-life 11 hours pt ed: sedation 40% ; , hypersalivation 30% ; , dizziness 20% ; constipation 15%, encourage fiber and fluids ; , headache, tachycardia, hyperthermia drug interactions: cimetidine tagamet ; can increase levels [substitute with ranitidine zantac ; ] fluvoxamine can double clozapine levels tcas increase risk of seizures, cardiac changes, sedation contraindications: absolute: anaphylactic reaction, comatose state, concomitant use of epinephrine for shock relative: pregnancy, hx of agranulocytosis, leukemia, nms, narrow angle glaucoma, hepatic or renal dysfunction, prostatic hypertrophy, parkinsons, severe cardiovascular disease avoid: drugs which can suppress bone marrow function: carbamazepine, sulfonamides, captopril clinical: monitor hypotension and tachycardia more carefully in first month and prozac and Buy haldol. FDA - Adverse Event Reporting System AERS ; Freedom Of Information FOI ; Report Corrected Interval Prolonged Extrapyramidal Disorder Eyelid Oedema Dose Duration Fall OROPHARINGEAL Hepatitis OROPHARINGEAL Infection OROPHARINGEAL Nephropathy Toxic OROPHARINGEAL Oedema Peripheral OROPHARINGEAL Qrs Axis Abnormal 1 tablet Quilonum Retard 2 tablets Quilonum Retard 1 tablet Quilonum Retard 1 tablet Ergenyl OROPHARINGEAL Ergenyl OROPHARINGEAL Ergenyl OROPHARINGEAL Ergenyl OROPHARINGEAL Ergenyl OROPHARINGEAL Ergenyl OROPHARINGEAL Ergenyl OROPHARINGEAL Quilonum Retard 2.5 tablets Quilonum Retard 2.5 tablets Quilonum Retard 1.5 tablets Quilonum Retard 2 tablets Haldol OROPHARINGEAL SS SS SS Quilonum Retard SS Risperdal SS Risperdal SS Risperdal SS Risperdal SS Risperdal PS.

C Ets: Exfrepyramatef Sy, spome EPS ; - EPS during the administration of HALDOL haloperidol ; have been reported frequently, often during the first few days of treatment EPS can akathisia, ordystoma indudingopisthotonos and oculogyric crisis ; . While all can occur at relatively low doses, they occur more frequently and with greater severity at higher doses. The symptoms may be controlled with dose reductions or administration of antiparkinson drugs such as benztropine mesytate USP or trihexyphenidyl hydrochloride USP. It should be noted that persistent EPS have been reported; the drug may have to be discontinued in such cases. Withdrawal Emergent Nurologlcal Signs Abrupt discontinuation of short-term anti-psychotic therap, is generally uneventful. However, some patients on maintenance treatment experience transient dysldnetic signs after abrupt withdrawal. In certain cases these are Indistinguishable from Tardive DySIdneSIa except for duration. It is unknown whether gradual withdrawal will reduce the occurrence of these signs, but until further evidence is available HALDOL should be gradually withdrawn.Twdlve Dyakkwela As with all a syndrome consisting of potentially irreversible, involuntary, dysklnetic movements, may appear in some patients on long-term therapy or may occur afterdrugtherapy has been discontinued. The risk appears to be greater in elderly patients on high-dose therapy, especially females. The symptoms are persistent and in some patients appear irreversible. The syndrome is characterized by rhythmical involuntary movements of tongue, face, mouth or jaw e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements ; . Sometimes these may be accompanied byinvoluntary movements ofextremities and the trunk. There is no known effective treatment fortardivedyskinesia; antiparldnson agents usually do not alleviatethe symptomsoftttis syndrome. It is suggestedthatall antipsychotic agents be discontinued Ifthese symptoms appear. Should ft be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent this syndrome may be masked. It has been reported that fine vermicular movementofthe tongue may be an early sign of tardive dysldnesia and If the medication is stopped at that time the full syndrome may not develop. Tardlve Dyatonla Tardive dystonia, not associated with the above syndrome, has also been reported. Tardlve dystonis is characterized by delayed onset of choreic or dystonic movements, is often persistent, and has the potential of becoming Irreversible. OtharCNSEIfecfs-lnsomnia, restlessness, anxiety, euphoria, agitation, drowsiness, depression, lethargy, headache, confusion, vertigo, grand mal seizures, and exacerbaton of psychotic symptoms including hallucinations, and catatonic-like behaviOral states which may be responsive to drug withdrawal and or treatment with anticholinergic drugs. B aw a Wlrol: Neuroleptic malignant syndrome NMS ; , hyperpyrexia and heat stroke have been reported with HALDOL. See WARNINGS for further information concerning NMS. ; cwetova.cufer Effects: Tachycardia, hypotension, hypertension and ECG changes, including prolongation of the O-T interval and ECG pattern changes compatible with the polymorphous configuration of torsades do pointes. l.eatoIo9Ic Effects: Reports of mild, usually transient leukopenia and leukocytosis, minimal decreasesinredbloodcellcounts, anernia, agranulocytosis rarely reported and only in association with other medication. LI EScta: Impaired liver function and or jaundice. wetoWIc Racflons: Maculopapular and acneiform reactions, isolated cases of photosensitivity, loss of hair. Endocs * i# Disorders: Lactation, breast engorgement, mastalgia, menstrual irregularities, gynecomastia, impotence, increased libIdo, hyperglycemia, hypoglycemia and hyponatrentia. Gaafrohi!.afktaI Effects: Anorexia, constipation, diarrhea, hyper-salivation, dyspepsia, nausea and vomiting. Aufancmlc ctIons: Dry mouth, blurred vision, urinary retention, diaphoresis, and priapism. Aeeto.jr Effects: Laryngospasm, bronchospasm and increased depth of respiration. Special Sarraee: Cataracts, retinopathy and visual disturbances. OfI: Cases of sudden and unexpected death have been reported in association with the administration of HALDOL The nature ofthe evidence makes it impossibletodetermine defin whatrole, Ifany, HALDOiplayed intheoutcome ofthe reportedcases. The possibilitythat HA causeddeathcannot, ofcourse, beexcluded, butitistobe keptin mindthatsudden andunexpected death may occur in psychotic patients when they go untreated or when they are treated with other a drugs. POafnw * .fbig Events: Hyperammonemia has been reported in a 51 year old child with cltrullinemia, an inherited disorder of ammonia excretion, following treatment with HALDOL. IMPORTANT: Full dIrections for uss should be read before HALDOL or HALDOL D.csnoat and desyrel. Conversion and antiarrhythmic drug therapy initial management as described for atrial flutter see Section V-F ; . ASD indicates atrial septal defect; PSVT, paroxysmal supraventricular tachycardia.

What is Haldol Withdrawal In certain cases these are indistinguishable from Persistent Tardive Dyskinesia' ` except for duration It is unknown whether gradual withdrawal will reduce the occurrence of these signs. but until further evidence is available haloperidol should be gradually withdrawn Persistent Tardive Dyslcinesia Although rarely reported with HALDOL haloperidol. tardive dyskinesia may appear during or after long-term therapy. The risk appears to be greater in elderly patients on high-dose therapy. especially females Symptoms are persistent and sometimes appear irreversible. there is no known effective treatment and all antipsychotic agents should be discontinued The syndrome may be masked by reinstitution of drug. increasing dosage. or switching to a different antipsychotic agent Other CNS Effects Insomnia, restlessness, anxiety. euphoria, agitation. drowsiness. depression. lethargy. headache, confusion, vertigo. grand mal seizures, and exacerbation of psychotic symptoms Cardiovascular Effects: Tachycardia and hypofension Hematologic Effects: Reports of mild, usually transient leukopenia and leukocytosis. minimal decreases in red blood cell counts. anemia, or a tendency toward lymphomonocytosis. agranulocytosis rarely reported and only in association with other medication Liver Effects: Impaired liver function and or laundice reported Dermatologic Reactions: Maculopapular and acneiform reactions, isolated cases of photosensitivity. loss of hair Endocrine Disorders: Lactation. breast engorgement. mastalgia. menstrual irregularities. gynecomastia, impotence. increased libido. hyperglycemia and hypoglycemia Gastrointestinal Effects: Anorexia, constipation . diarrhea, hypersalivation. dyspepsia. nausea and vomiting. Autonomic Reactions: Dry mouth. blurred vision. urinary retention and diaphoresis. Respiratory Effects: Laryngospasm. bronchospasm and increased depth of respiration. The inlectable form is intended only for acutely agitated psychotic patients with moderately severe to very severe symptoms Caution: Federal law prohibits dispensing without prescription. Full directions for use should be read before HALDOL haloperidol is administered or prescribed. HALDOL tablets are manufactured by McNeil Laboratories Co. Dorado. What is Haldol Recordings, and bicycle stress testing with oxygen consumption were used to document PAF and to exclude sinus node disease and abnormal atrioventricular conduction. Two-dimensional and pulsedwave Doppler echocardiographic studies were performed to measure cardiac chamber size and function and to exclude structural cardiac disease. Left and right heart catheterization and coronary angiography were performed to rule out cardiac abnormalities and to obtain information on the arterial supply of the sinus node area. Catheter mapping of AF for detecting a focal origin or classifying the arrhythmia was not done. Haldol ointment Hald9l, jaldol, hakdol, ualdol, halfol, halcol, yaldol, haldkl, hwldol, hhaldol, ahldol, haldil, haldoo, naldol, haldop, haaldol, hxldol, hqldol, haldl, hldol, haldool, aldol, halsol. © 2007